TCM
TCG Crossover Management Portfolio holdings
AUM
$2.03B
1-Year Est. Return
373.29%
1 Year Est. Return
+373.29%
AUM
$876M
AUM Growth
+$142M
(+19%)
Holding
40
Top Sells
| 1 | +$39.2M | |
| 2 | +$11M | |
| 3 | +$7.44M | |
| 4 |
Kura Oncology
KURA
|
+$3.97M |
| 5 |
THRD
Third Harmonic Bio
THRD
|
+$3.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Enliven Therapeutics
ELVN
$1.27B
| $9.99M | 1.14% |
+498,000
|
|
||
|
MBX
27
MBX Biosciences
MBX
$1.15B
| $7.42M | 0.85% |
650,000
|
|
||
28
Nektar Therapeutics
NKTR
$1.19B
| $6.89M | 0.79% |
266,666
-1
|
|
||
29
VistaGen Therapeutics
VTGN
$137M
| $5.35M | 0.61% |
2,676,580
|
|
||
30
Kodiak Sciences
KOD
$1.06B
| $4.27M | 0.49% |
1,145,538
|
|
||
|
31
Kura Oncology
KURA
$942M
| $4.24M | 0.48% |
735,184
-688,458
|
|
||
32
Entrada Therapeutics
TRDA
$317M
| $3.93M | 0.45% |
584,955
|
|
||
33
Adverum Biotechnologies
ADVM
$93.7M
| $3.86M | 0.44% |
1,796,482
|
|
||
34
Avalo Therapeutics
AVTX
$301M
| $2.41M | 0.28% |
483,000
|
|
||
35
Ventyx Biosciences
VTYX
$669M
| $677K | 0.08% |
316,195
|
|
||
|
JBIO
36
Jade Biosciences
JBIO
$573M
| $640K | 0.07% |
64,023
|
|
||
37
Cabaletta Bio
CABA
$228M
| $132K | 0.02% |
86,795
|
|
||
38
Mineralys Therapeutics
MLYS
$3.42B
| – | – |
-2,470,265
|
|
||
39
Keros Therapeutics
KROS
$525M
| – | – |
0
|
|
||
|
CMPS
40
Compass Pathways
CMPS
$520M
| – | – |
-3,858,000
|
|